XNAS
STTK
Market cap55mUSD
Jun 10, Last price
1.16USD
1D
-2.52%
1Q
-5.69%
IPO
-93.89%
Name
Shattuck Labs Inc
Chart & Performance
P/E
—
P/S
9.71
EPS
—
Div Yield, %
—
Shrs. gr., 5y
3.99%
Rev. gr., 5y
-10.36%
Revenues
6m
+245.26%
Net income
-75m
L-13.62%
CFO
-61m
L-25.50%
Earnings
Jul 30, 2025
Profile
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 5,721 245.26% | 1,657 154.14% | 652 -97.83% | ||||
Cost of revenue | 86,288 | 97,656 | 107,356 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (80,567) | (95,999) | (106,704) | ||||
NOPBT Margin | |||||||
Operating Taxes | (1,384) | ||||||
Tax Rate | |||||||
NOPAT | (80,567) | (95,999) | (105,320) | ||||
Net income | (75,410) -13.62% | (87,298) -13.19% | (100,561) 126.75% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | (17) | 48,170 | 171 | ||||
BB yield | 0.03% | -15.86% | -0.18% | ||||
| Debt | |||||||
Debt current | 796 | 701 | |||||
Long-term debt | 5,012 | 6,812 | 8,404 | ||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | (67,975) | (123,017) | (152,175) | ||||
| Cash flow | |||||||
Cash from operating activities | (60,515) | (81,228) | (94,498) | ||||
CAPEX | (59) | (407) | (11,614) | ||||
Cash from investing activities | (8,511) | 110,859 | 49,438 | ||||
Cash from financing activities | 787 | 48,616 | 171 | ||||
FCF | (74,637) | (94,070) | (113,053) | ||||
| Balance | |||||||
Cash | 72,987 | 130,625 | 161,280 | ||||
Long term investments | |||||||
Excess cash | 72,701 | 130,542 | 161,247 | ||||
Stockholders' equity | (381,713) | (306,301) | (219,884) | ||||
Invested Capital | 463,845 | 455,208 | 400,944 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 50,758 | 42,600 | 42,379 | ||||
Price | 1.21 -83.03% | 7.13 210.00% | 2.30 -72.97% | ||||
Market cap | 61,418 -79.78% | 303,739 211.62% | 97,471 -72.75% | ||||
EV | (6,557) | 180,722 | (54,704) | ||||
EBITDA | (76,738) | (91,957) | (103,631) | ||||
EV/EBITDA | 0.09 | 0.53 | |||||
Interest | 3,073 | ||||||
Interest/NOPBT | |||||||